Ohio State Early Investor Network’s Post

Congratulations to Kotaro Nakanishi, Associate Professor, at The Ohio State University on the launch of this new promising startup. Learn more about his exceptional research and career https://lnkd.in/eqihNKhN #biomedical #genetherapy | City Therapeutics

🔙 #ThrowbackThursday to a paper that delves into how the SILCS methodology isn't only able to be used on protein's but can also be used on RNA targets as well if the structure of the RNA is known. 📄 Title: SILCS-RNA: Toward a Structure-Based Drug Design Approach for Targeting RNAs with Small Molecules 👥 Authors: Abhishek A. Kognole, Anthony Hazel, and Alexander D. MacKerell, Jr. 📅 Published: September 13th, 2022 🔗 Link: https://lnkd.in/drwZU2sa RNA molecules hold promise as potential therapeutic targets, given their involvement in various diseases. Noncoding RNAs, constituting about 70% of the human genome, exhibit complex tertiary structures, making them attractive for small molecule targeting. In this study, we extended the Site Identification by Ligand Competitive Saturation (SILCS) computational approach to target RNA, termed SILCS-RNA. With this study, the method was rigorously evaluated against seven RNA targets and their known small molecule ligands. SILCS-RNA provides detailed insights into functional group affinity patterns within small molecule binding sites, facilitating ligand design by identifying potential new binding sites and crucial ligand moieties. Learn more about how SILCS-RNA is being used by our customers by contacting us: https://lnkd.in/eMY8Y95D #ComputationalChemistry #MolecularModeling #ComputationalDrugDesign #ChemicalInformations #RNADrugDesign

Oligonucleotide therapeutics represent a cutting-edge area of medicine that utilizes nucleic acids to target and treat diseases at the molecular level. These are transforming the landscape of modern medicine. With ongoing research and development, they offer promising solutions for a wide array of diseases, making them an exciting area for both scientific and clinical advancements. 🌐 Join the Conversation! 💡 We are excited to announce the 2nd and 3rd Editions of the Oligonucleotide Therapeutics and Delivery Conferences! 🗓 Rome, Italy: June 9-10, 2025 🗓 San Francisco, CA, USA: August 18-19, 2025 💫 Topics of Interest: Antisense oligonucleotides and siRNA technologies mRNA therapeutics and applications Innovative delivery systems and strategies Gene editing and regulatory considerations Why You Should Attend: Gain Knowledge: Hear from top researchers and industry experts about the latest developments in oligonucleotide therapies and their applications. Networking Opportunities: Meet and connect with like-minded professionals who share your passion for RNA science. Future Focused: Participate in forward-thinking discussions about the potential of RNA technologies in personalized medicine and beyond. Don’t Miss Out! This is your chance to contribute to the future of healthcare innovation! Join us in driving the next wave of oligonucleotide therapeutics! For submission guidelines and more information, please visit: 🔗 https://lnkd.in/ehG6wf6g To contact us ⬇ 📩 Email Id: asmith@sciinovhealth.com #OligonucleotideTherapeutics #RNA #Innovation #Conferences #Rome2025 #SanFrancisco2025 #Immunology #microRNA #RNAediting #NucleicAcidTherapeutics #ClinicalResearch #RNAandoligoTherapeutics #RNATherapeutics #CRISPR #OligochemistryToolsandTechnologies #Toxicity #rnai #geneediting #genetherapy #sirna #lna #delivery #systems #drugs #dynamics #pharmacology #drugresearch #drugdevelopment #therapeutics #genes #coding #rna #researchers #Italy #USA #speakers #hybrid #online #OTDC2025 #Sharethepost

Drug Discovery News has published a very interesting article about #circularRNA and its significant advantages and promising #therapeutic future in comparison to #linearRNA and #mRNA. This results from a Q&A interview between Luisa Torres, PhD, Science Editor and Erik Digman Wiklund, CEO of Circio Holding ASA . As the co-discoverer of circular #RNA, Erik is the equal first most qualified person to discuss this, alongside the other co-discoverer, Thomas Hansen, Circo's CTO. Erik discusses the discovery, why #circRNA is so important, why Circio chose #AATD as a lead target, and the future of the circRNA and wider RNA fields. Really interesting to work with Circio and be part of the examination into the future of RNA and #genetherapy. https://lnkd.in/eANY7nN5

Does single-cell data increase probability of success in drug discovery and clinical phases? 🧐 Drug targets backed by single-cell data are x3 likely to reach phase III, when combined with genetic data 🎯 Read the pre-print of this brilliant study by Sanofi and Wellcome Sanger Institute here: https://lnkd.in/dwMYiBCx Human Cell Atlas project and single-cell omics promised to transform biology and medicine. This is proof for that promise: a demonstrated and quantified impact of single-cell target analysis on clinical success with clear examples & explanations 🙌 Congratulations to the team behind the study for tackling a research question many of us has been pondering over for years. A prominent example of industry x academic collaboration 💪 Emma Dann and Sarah Teichmann FMedSci FRS at Wellcome Sanger Institute, Erin Teeple, Virginia Savova, Ph. D. , Emanuele de Rinaldis and team at Sanofi, and Rasa Elmentaite at Ensocell. #DrugDiscovery #TargetDiscovery #SingleCellOmics #RnD

After a steep drop of about 40 percent in the share price on April 2 following the news, Verve Therapeutics appears not to have disappeared into the night (a la Graphite Bio) but instead lives to fight another day behind other pipeline leads, VERVE-102 and VERVE-201, which both use a different lipid nanoparticle (LNP) system than VERVE-101. That’s significant given that Kathiresan insists it was neither the guide RNA nor the base editing process that caused the SAE. There are three parts of the drug—the single-guide (sg) RNA, the mRNA encoding the base editor, and the LNP, Kathiresan explains. Two of the three are working as designed—the guide and the editor. The culprit, Kathiresan believes, is the LNP. 

It's no secret that RNA research has been a driving force behind the recent therapeutic advancements in biopharma. As we continue to push the envelope on what's possible in this field, it's important not to forget the foundational research that laid the groundwork for these breakthroughs. Let's take a moment to acknowledge the basic research on RNA that has enabled the most recent boom in its therapeutic potential. #biopharma #RNA #RNAresearch #therapeuticadvancements

It's an exciting time to be involved in the RNA field, especially with the backing and direction provided by Australia's RNA Blueprint. This initiative highlights our ribonucleic acid (RNA) potential and outlines the steps that governments, academia, and industry can take to foster the growth of Australia's #RNA sector.   #oligonucleotides #biotechnology

📢 AusBiotech welcomes today’s release of Australia’s RNA Blueprint, building on the existing Medical Science Co-investment Plan. There’s no doubt that advanced therapies developed using RNA-based technologies are at the forefront of Australia’s therapeutic revolution in medicine. Immunogenicity, capacity for rapid development and safe administration, when compared to conventional platforms such as small molecules and proteins, mean they hold great promise for new therapies and new standards of care. We’re proud that a number of our members are already engaging in home grown RNA research and development right here in Australia.     We are also pleased to see Australia’s Cell & Gene Catalyst, a joint venture between AusBiotech and Medicines Australia, recognised for its potential as a strategic partner to bring the ecosystem together, and collaborate for impact by enabling connection and collaboration at the national level. The Catalyst aims to accelerate the development, manufacture and commercialisation of cell and gene therapies, including RNA, to foster a prosperous cell and gene industry in Australia.   We look forward to working with Government to bring the Blueprint into action. Read more here: https://lnkd.in/g-xQxC2r   The Hon. Ed Husic MP, Minister for Industry and Science, the Hon. Mark Butler MP, Minister for Health and Aged Care, Cell Therapies Pty Ltd CSL Behring, Novartis, Pfizer, Roche, Therapeutic Innovation Australia #MinisterHusic #MinisterButler #RNA #RNABlueprint #AusBiotech #MedicinesAustralia #AustraliasCellandGeneCatalyst

𝐏𝐀𝐑𝐏 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 2024-2031 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 & 𝐓𝐫𝐞𝐧𝐝𝐬 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐃𝐞𝐦𝐨 𝐑𝐞𝐩𝐨𝐫𝐭, 𝐄𝐱𝐜𝐞𝐥 𝐏𝐢𝐯𝐨𝐭 𝐚𝐧𝐝 𝐓𝐨𝐂: https://lnkd.in/dZgZrPX3 #PARPInhibitorBiomarkers Market Size is valued at USD 897.8 Mn in 2023 and is predicted to reach USD 1,751.6 Mn by the year 2031 at a 8.8% CAGR during the forecast period for 2024-2031. ▪ 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐫𝐞: ▪ Myriad Genetics. ▪ Ambry Genetics ▪ Thermo Fisher Scientific ▪ Illumina. ▪ CENTOGENE ▪ Amoy Diagnostics., ▪ Invitae ▪ NeoGenomics Laboratories. ▪ QIAGEN ▪ Agilent Technologies, Inc. ▪ Wohlfahrtsstiftung der F. Hoffmann-La Roche AG ▪ Bio-Rad Laboratories. ▪ Exagen Inc. ▪ GenWay Biotech Inc ▪ Svar Life Science AB ▪ Siemens Healthcare Pvt. Ltd.  #Biomarkers #CancerResearch #MarketTrends #BreastCancer #OvarianCancer #MarketForecast